A new therapeutic drug for Alzheimer’s disease without inflammatory side effects

Although Aduhelm, a monoclonal antibody targeting amyloid beta (A?), recently became the first US FDA approved drug for Alzheimer’s disease (AD) based on its ability to decrease A? plaque burden in AD patients, its effect on cognitive improvement is still controversial. Moreover, about 40% of the patients treated with this antibody experienced serious side effects including cerebral edemas (ARIA-E) and hemorrhages (ARIA-H) that are likely related to inflammatory responses in the brain when the A? antibody binds Fc receptors (FCR) of immune cells such as microglia and macrophages. Now there is a new option.
Read Original Article: A new therapeutic drug for Alzheimer’s disease without inflammatory side effects »